Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata

Guide to Receptors and Channels (GRAC), 5th edition

(2011) SPH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease

(2010) Susan Duty   BRITISH JOURNAL OF PHARMACOLOGY

Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease

(2010) PJ Austin et al.   BRITISH JOURNAL OF PHARMACOLOGY

Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism

(2009) Corinne Beurrier et al.   FASEB JOURNAL

mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease

(2009) Corey R Hopkins et al.   Future Medicinal Chemistry

Metabotropic Glutamate 7 Receptor Subtype Modulates Motor Symptoms in Rodent Models of Parkinson's Disease

(2009) B. Greco et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4

(2008) C. M. Niswender et al.   MOLECULAR PHARMACOLOGY

AMN082, an allosteric mGluR7 agonist that inhibits afferent glutamatergic transmission in rat basolateral amygdala

(2008) Annarosa Ugolini et al.   NEUROPHARMACOLOGY

Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo

(2007) Nicholas MacInnes et al.   EUROPEAN JOURNAL OF PHARMACOLOGY